Formerly promising Pharmos nearing the end of its rope

Pharmos was an early contender in the field of nanomedicine, with a nanoemulsion drug delivery technology it was developing for osteoarthritis pain (see the March 6, 2007 LRNJ). We recently spoke with Colin Neill, the company's current CEO, to get an update. Colin told us that the company has signif...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Pear Therapeutics CEO claims Novartis trial of schizophrenia therapeutic was flawed; tensions grow between digital therapeutics and pharma

News Commentary | April 16, 2021

The CEO of Pear Therapeutics is claiming that trial irregularities are causing misleading results regarding the schizophrenia product rolled out last year. While the results of this study are unlikely to change anything for Pear Therapeutics directly, the claimed lack of rigor in the trial speaks to... Not part of subscription

Pfizer will acquire Trillium Therapeutics for $2.26 billion, seeking to further boost its capabilities in oncology

News Commentary | August 27, 2021

Trillium is a developer of a novel immunotherapy solution that targets a molecule called CD47 on cancer cells. In healthy cells, CD47 plays a part in displaying a "don't‑eat‑me" signal to the immune system. Malignant cancer cells display these molecules on their surface to evade the immune system. ... Not part of subscription

Akili Interactive is going public, expected to net USD 412 million and open up investment opportunities

News Commentary | February 01, 2022

The company will be going public through a special purpose acquisition company known as Social Capital Suvretta Holdings Corp. Akili Interactive will use the expected cash proceeds to support the rollout of their U.S. FDA‑approved pediatric ADHD therapeutic, EndeavorRx. With EndeavorRX, Akili is ... Not part of subscription